TopiVert
TopiVert is a London-based, privately-held biopharmaceutical venture founded in 2011, spun out of the Imperial College London ecosystem and backed by specialized life-sciences investors across three funding rounds through 2016; the company's current operational status is unclear, with its primary domain listed for sale.
- Company typePrivate
- Founded2011
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What TopiVert does
TopiVert is a privately-held, London-based biopharmaceutical company founded in 2011 that originated from the Imperial College London innovation ecosystem, with Imperial Innovations serving as the founding lead investor. The company attracted specialized life-sciences venture capital across three funding rounds between 2011 and 2016, raising a disclosed total of approximately $19.9M from Imperial Innovations, SV Health Investors, Johnson & Johnson Development Corporation, and Neomed Management. Leadership consisted of founder Eric Charles Meldrum and Chief Scientific Officer Steve Webber, with headcount in the 11-50 range typical of clinical-stage biotech ventures.
The company's therapeutic focus, specific pipeline assets, and underlying technology platform are not disclosed in the available source data; no products, services, clinical programs, patents, or partnerships are described beyond investor participation. The most recent source signal indicates that the company's primary web domain, topivert.com, is currently listed for sale on HugeDomains for $10,595 and hosts no operational content, which suggests the entity is no longer actively maintaining a digital presence. There is no disclosed revenue model, pricing mechanism, go-to-market motion, or customer base in the source material.
TopiVert firmographics
Firmographics- Name
- TopiVert
- Website
- https://topivert.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- TopiVert is a London-based, privately-held biopharmaceutical venture founded in 2011, spun out of the Imperial College London ecosystem and backed by specialized life-sciences investors across three funding rounds through 2016; the company's current operational status is unclear, with its primary domain listed for sale.
- Ownership category
- akta.pro rank
TopiVert industry classification
Industry- Product category
- Clinical-stage biopharmaceutical R&D
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- Translational Medicine & Biomarkers (HLAIALAF), Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
Keywords
Where TopiVert is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
TopiVert business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
TopiVert product offering
Product offeringCore offering
TopiVert developed and advanced clinical-stage, topical therapeutic candidates targeting inflammatory diseases of the gastrointestinal tract, leveraging pioneering university-originated biopharmaceutical technology. The company's work was structured around translational drug discovery and early-stage clinical development intended to support licensing or partnership deals with larger pharmaceutical firms.
Product overview
No product or service information for TopiVert is available in the source data. The only TopiVert-related webpage identified is a domain for sale page (topivert.com) hosted by HugeDomains, which contains no information about the company's actual products, services, or technology offerings.
Differentiator
Problem solved
Functional benefit
Products and services
- Topical therapeutic pipeline for inflammatory GI disease A pipeline of topical therapeutic candidates intended for treatment of inflammatory diseases of the gastrointestinal tract, developed for eventual in-licensing, partnership, or further development by larger pharmaceutical companies. Targeted at pharmaceutical partners rather than end consumers.
Companies that use TopiVert
Customer profileIdeal customer profiles1 record
TopiVert technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
TopiVert partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights3 records
TopiVert competitors and assessment
Company assessmentDirect peers
- Alimentiv (formerly Robarts Clinical Trials): CRO and clinical research organization specialized in inflammatory bowel disease and gastrointestinal clinical trials. TopiVert developed therapeutics in the same IBD/GI specialty area, making Alimentiv a directly comparable peer in trial execution and disease focus.
- Abivax: European clinical-stage biotech developing oral small-molecule therapies for inflammatory diseases including ulcerative colitis. Closely comparable to TopiVert in therapeutic area (IBD/GI inflammation), modality (small molecules), and stage of development.
- Morphic Therapeutic: Clinical-stage biotech developing oral integrin inhibitors for autoimmune and inflammatory diseases including IBD. Directly comparable in target space, modality, and indication overlap with TopiVert's inflammatory disease focus.
- Ardelyx: Specialty pharma focused on gastrointestinal and cardiorenal diseases, with approved and pipeline assets in IBS-C, hyperphosphatemia, and related GI conditions. Comparable as a specialty GI therapeutics developer with similar scale and strategic focus.
- Ironwood Pharmaceuticals: GI-focused specialty pharma commercializing Linzess for IBS-C/CIC and developing additional GI assets. Comparable in therapeutic area focus and small-molecule GI drug development model.
- RedHill Biopharma: Specialty pharma with marketed GI products (e.g., Talicia, Aemcolo) and a pipeline addressing H. pylori, IBS, and other GI conditions. Directly comparable in GI therapeutic focus and small-molecule development strategy.
- Theravance Biopharma: Specialty pharma with legacy GI/opioid-induced constipation franchise and inflammatory disease pipeline. Comparable in specialty pharma positioning, GI therapeutic area, and small-molecule development history.
Broad incumbents
- Galapagos NV: European clinical-stage biotech with a broad inflammation/immunology pipeline including IBD candidates (filgotinib, Jyseleca). Comparable as a larger European inflammation player overlapping with TopiVert's therapeutic area.
- Prometheus Biosciences (now Merck): Was a clinical-stage immunology company focused on IBD (acquired by Merck for ~$10.8B in 2023). Comparable as a peer IBD-focused biotech that successfully exited via large-pharma acquisition — useful as a comparable exit scenario.
Others
- SV Health Investors (formerly SV Life Sciences): Specialist healthcare venture and growth investor and a key backer of TopiVert. Listed as a peer for ecosystem reference rather than direct competition; relevant as a repeat co-investor in the European specialty pharma space.
Market position
Weaknesses3 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
TopiVert social profiles
Digital presenceTopiVert financial estimates
Financial estimateRevenue estimate
Valuation estimate
TopiVert leadership team
Management profileNumber of profiles
Profiles2 records
TopiVert funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TopiVert M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TopiVert
What does TopiVert do?
TopiVert developed and advanced clinical-stage, topical therapeutic candidates targeting inflammatory diseases of the gastrointestinal tract, leveraging pioneering university-originated biopharmaceutical technology. The company's work was structured around translational drug discovery and early-stage clinical development intended to support licensing or partnership deals with larger pharmaceutical firms.
When was TopiVert founded?
TopiVert was founded in 2011. It employs 11 to 50 people.
Where is TopiVert based?
TopiVert is headquartered in London, United Kingdom, in the Europe region.
Who are TopiVert's main competitors?
Direct peers on record are Alimentiv (formerly Robarts Clinical Trials), Abivax, Morphic Therapeutic, Ardelyx, Ironwood Pharmaceuticals, RedHill Biopharma and Theravance Biopharma. Broad incumbents are Galapagos NV and Prometheus Biosciences (now Merck). SV Health Investors (formerly SV Life Sciences) is listed as an others.
Does TopiVert have an API?
No public API is recorded for TopiVert.
What industry is TopiVert in?
TopiVert's product category is Clinical-stage biopharmaceutical R&D. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 2834.